Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 613

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

Open access
Goyal, Lipika, Meric-Bernstam, Funda, Hollebecque, Antoine, Valle, Juan W., Morizane, Chigusa, Karasic, Thomas B., Abrams, Thomas A., Furuse, Junji, Kelley, Robin K., Cassier, Philippe A., Klümpen, Heinz-Josef, Chang, Heung-Moon, Chen, Li-Tzong, Tabernero, Josep, Oh, Do-Youn, Mahipal, Amit, Moehler, Markus, Mitchell, Edith P., Komatsu, Yoshito, Masuda, Kunihiro, Ahn, Daniel, Epstein, Robert S., Halim, Abdel-Baset, Fu, Yao, Salimi, Tehseen, Wacheck, Volker, He, Yaohua, Liu, Mei, Benhadji, Karim A., Bridgewater, John A.·2023·New England Journal of Medicine

Abstract

BACKGROUND: -altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors. METHODS: rearrangement-positive intrahepatic cholangiocarcinoma and disease progression after one or more previous lines of systemic therapy (excluding FGFR inhibitors). The patients received oral futibatinib at a dose of 20 mg once daily in a continuous regimen. The primary end point was objective response (partial or complete response), as assessed by independent central review. Secondary end points included the response duration, progression-free and overall survival, safety, and patient-reported outcomes. RESULTS: mutations. At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months. Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%). Treatment-related adverse events led to permanent discontinuation of futibatinib in 2% of the patients. No treatment-related deaths occurred. Quality of life was maintained throughout treatment. CONCLUSIONS: fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2206834

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 613

Metadata

Authors
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klümpen, H.-J., Chang, H.-M., Chen, L.-T., Tabernero, J., Oh, D.-Y., Mahipal, A., Moehler, M., Mitchell, E. P., Komatsu, Y., Masuda, K., Ahn, D., Epstein, R. S., Halim, A.-B., Fu, Y., Salimi, T., Wacheck, V., He, Y., Liu, M., Benhadji, K. A., & Bridgewater, J. A.
Venue
New England Journal of Medicine
Published
2023-01-19
Volume
388
Issue
3
Pages
228-239
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4317355154
Cited by
613
References
37
FWCI
145.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma. https://app.cochat.ai/papers/10.1056/nejmoa2206834
The paper
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klümpen, H.-J., Chang, H.-M., Chen, L.-T., Tabernero, J., Oh, D.-Y., Mahipal, A., Moehler, M., Mitchell, E. P., Komatsu, Y., . . . Bridgewater, J. A. (2023). Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.